Introduction: Integrating Incretin-Based Therapies Into Diabetes Care

The management of type 2 diabetes has evolved significantly over the past two decades, moving from a primarily insulin-centric model to one that leverages multiple hormonal pathways. Incretin-based therapies—including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors—have become cornerstone agents in modern treatment protocols. By targeting the body's natural incretin system, these medications improve glycemic control with a lower risk of hypoglycemia and often provide additional benefits in weight management and cardiovascular health. This article provides a comprehensive overview of the role of incretin-based therapies in contemporary diabetes management, including their mechanisms, clinical evidence, practical considerations, and future directions.

Physiology of the Incretin System

The incretin effect refers to the observation that oral glucose elicits a much stronger insulin response than intravenous glucose at equivalent blood glucose levels. This phenomenon is driven by gut-derived hormones, primarily glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Both hormones are secreted from intestinal L-cells and K-cells, respectively, in response to nutrient ingestion.

GLP-1 binds to receptors on pancreatic beta cells, potentiating glucose-stimulated insulin secretion. It also suppresses glucagon release from alpha cells, delays gastric emptying, and promotes satiety. GIP similarly stimulates insulin secretion but does not consistently suppress glucagon. In type 2 diabetes, the incretin effect is blunted, partly due to reduced GLP-1 secretion and diminished beta-cell responsiveness. This deficit provides the rationale for pharmacologically augmenting incretin activity.

Classes of Incretin-Based Agents

GLP-1 Receptor Agonists

GLP-1 receptor agonists (GLP-1 RAs) are synthetic analogs of native GLP-1 that are resistant to degradation by DPP-4. They mimic the actions of endogenous incretin hormones. Currently available agents include:

  • Exenatide (twice-daily and once-weekly formulations)
  • Liraglutide (once-daily, also approved for weight management)
  • Dulaglutide (once-weekly)
  • Semaglutide (once-weekly injectable and oral formulation)
  • Tirzepatide (a dual GIP/GLP-1 receptor agonist, once-weekly)

These agents vary in half-life, dosing frequency, and efficacy. Semaglutide and tirzepatide have demonstrated superior glycemic and weight loss outcomes in head-to-head trials. GLP-1 RAs are recommended as first-line injectable therapy after metformin in patients with established cardiovascular disease, chronic kidney disease, or obesity.

DPP-4 Inhibitors

DPP-4 inhibitors (also called gliptins) prevent the enzymatic breakdown of endogenous GLP-1 and GIP, thereby raising their circulating levels. Drugs in this class include:

  • Sitagliptin (once-daily)
  • Saxagliptin (once-daily)
  • Linagliptin (once-daily, primarily excreted via bile)
  • Alogliptin (once-daily)
  • Vildagliptin (twice-daily, not approved in all regions)

DPP-4 inhibitors are generally weight-neutral, have a low risk of hypoglycemia, and are well tolerated. They provide moderate reductions in HbA1c (0.5–0.8%) and are often used as add-on therapy to metformin or as an alternative when GLP-1 RAs are not tolerated or contraindicated.

Clinical Efficacy and Glycemic Outcomes

Numerous randomized controlled trials and real-world studies have established the glycemic efficacy of incretin-based therapies. A meta-analysis of over 50 trials involving GLP-1 RAs reported mean reductions in HbA1c of 1.0–1.5% from baseline, with greater effects seen with higher doses and longer-acting formulations. DPP-4 inhibitors produce more modest reductions, typically 0.5–0.8%.

Importantly, incretin-based agents exhibit glucose-dependent insulin secretion, meaning they stimulate insulin release only when blood glucose is elevated. This mechanism substantially reduces the risk of hypoglycemia compared with sulfonylureas or insulins. In trials such as LEADER (liraglutide) and REWIND (dulaglutide), the incidence of severe hypoglycemia was similar to placebo.

Beyond Glycemic Control: Cardiovascular and Weight Benefits

Cardiovascular Outcomes

One of the most transformative findings in diabetes therapeutics is the cardiovascular safety and benefit of certain GLP-1 RAs. The landmark LEADER trial demonstrated that liraglutide reduced the risk of major adverse cardiovascular events (MACE) by 13% compared with placebo in patients with type 2 diabetes and high cardiovascular risk. Similar benefits were observed with semaglutide (SUSTAIN-6) and dulaglutide (REWIND). These agents also slow progression of diabetic kidney disease. In contrast, DPP-4 inhibitors have shown cardiovascular neutrality with no significant reduction or increase in MACE, except for saxagliptin which was associated with a slight increase in heart failure hospitalizations in the SAVOR-TIMI 53 trial.

Current guidelines from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend GLP-1 RAs as the preferred add-on therapy to metformin for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease (<sup>1</sup>).

Weight Management

GLP-1 RAs, particularly semaglutide and tirzepatide, induce significant weight loss through delayed gastric emptying and central appetite suppression. In the STEP trials, semaglutide 2.4 mg weekly resulted in mean weight reductions of 12–15% over 68 weeks. Liraglutide 3.0 mg is approved for chronic weight management in patients with or without diabetes. DPP-4 inhibitors are weight-neutral, a key distinction when selecting therapy for an overweight or obese patient.

Safety Profile and Adverse Effects

The most common adverse effects of GLP-1 RAs are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These symptoms are dose-dependent and often mitigate with gradual dose titration. Less common but serious adverse events include pancreatitis (rare), gallbladder disease (cholelithiasis, cholecystitis), and a potential risk of medullary thyroid carcinoma (based on animal studies, leading to a boxed warning). Retinopathy complications have been reported with rapid glycemic improvement, particularly with semaglutide, though the absolute risk is low.

DPP-4 inhibitors are generally well tolerated, with gastrointestinal side effects less common. Arthralgia (joint pain) has been reported, and cases of bullous pemphigoid have been observed, especially with long-term use. Pancreatitis risk is debated but appears to be very low. Linagliptin requires no dose adjustment in renal impairment, making it a useful option in chronic kidney disease.

Patient Selection and Protocol Integration

Incretin-based therapies are not suitable for everyone. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Caution is advised in patients with severe gastrointestinal disease (e.g., gastroparesis). For DPP-4 inhibitors, saxagliptin and alogliptin require dose adjustment for renal function, and saxagliptin carries a warning about heart failure risk.

In modern treatment protocols, incretin therapies are positioned as second-line agents after metformin, particularly when additional glycemic lowering is needed, when weight loss is desirable, or when cardiovascular risk reduction is paramount. The ADA/EASD consensus algorithm illustrates a decision tree that prioritizes GLP-1 RAs in patients with high-risk features, including a history of ASCVD, heart failure, or CKD with albuminuria <sup>2</sup>. DPP-4 inhibitors are considered for patients who are intolerant to GLP-1 RAs or who prefer oral therapy with minimal GI side effects.

Combination Therapy and Emerging Agents

GLP-1/GIP Dual Agonists

Tirzepatide, a first-in-class dual GIP and GLP-1 receptor agonist, has demonstrated superior reductions in HbA1c and weight compared with semaglutide in the SURPASS series of trials. It is approved for type 2 diabetes and is under investigation for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Dual and triple agonists (e.g., retatrutide, a GLP-1/GIP/glucagon triagonist) are in development, promising even greater metabolic benefits.

Oral GLP-1 RAs

Oral semaglutide (Rybelsus) provides an alternative to injections for patients who prefer oral administration. It is formulated with the absorption enhancer SNAC to facilitate bioavailability. Efficacy is somewhat lower than injectable semaglutide, but it still offers significant glycemic and weight benefits. Other oral GLP-1 RAs are in clinical trials.

Fixed-Dose Combinations

Combinations of incretin agents with other classes (e.g., insulin glargine/lixisenatide) offer convenience and synergistic effects. These fixed-ratio combinations, such as Soliqua (insulin glargine + lixisenatide) and Xultophy (insulin degludec + liraglutide), allow for lower insulin doses and less weight gain compared with insulin alone.

Challenges in Clinical Practice

Despite their efficacy, several barriers limit widespread use of incretin-based therapies:

  • Cost and access: GLP-1 RAs are expensive, and insurance formulary restrictions may require step therapy. Patient assistance programs exist but can be difficult to navigate.
  • Injection anxiety: Many patients are hesitant to initiate injectable therapies. Provider education and proper counseling can mitigate this. The availability of oral semaglutide and once-weekly injectable formulations improves adherence.
  • Gastrointestinal tolerability: Titration schedules and dose adjustment (e.g., starting with low doses, taking with meals) help minimize GI side effects. In some patients, persistence is required as tolerance develops over weeks.
  • Long-term safety monitoring: Post-marketing surveillance continues for rare events like pancreatitis and neoplasia. The thyroid C-cell tumor risk is a class warning based on rodent studies, but human data from large CVOTs (CVOTs like LEADER, REWIND) have not shown an increased incidence of MTC.

Future Directions: Personalized Protocols and Combination Therapies

As the understanding of underlying pathophysiology deepens, incretin-based therapies are likely to be used earlier in the disease course, potentially even as first-line therapy in selected populations. Ongoing research includes:

  • Primary prevention: Trials such as SELECT (semaglutide) and SURMOUNT (tirzepatide) are evaluating GLP-1 RAs for cardiovascular risk reduction in overweight/obese individuals without diabetes.
  • Combination with SGLT2 inhibitors: The combination of a GLP-1 RA and an SGLT2 inhibitor provides complementary cardiorenal benefits. This synergistic approach is increasingly recommended for high-risk patients <sup>3</sup>.
  • Weekly oral formulations: Advances in peptide delivery may yield once-weekly oral GLP-1 agents, further improving convenience.
  • Bariatric surgery mimetics: Multi-agonists that target GLP-1, GIP, and glucagon receptors aim to replicate the metabolic effects of bariatric surgery, including weight loss, improved glycemic control, and reductions in hepatic steatosis.

Real-world data and digital health tools (apps, remote monitoring) are helping to optimize adherence and dose titration. Personalized medicine approaches that consider genetic polymorphisms in GLP-1 receptor or GIP receptor pathways may eventually guide therapy selection.

Practical Protocol Example: Incretin Integration in a Stepwise Algorithm

Consider a typical patient with newly diagnosed type 2 diabetes (HbA1c 8.5%, BMI 32 kg/m², no clinical ASCVD). Step 1: Metformin at target dose with lifestyle modifications. Step 2: If HbA1c remains ≥7.5% after 3 months, add a GLP-1 RA (e.g., semaglutide 0.25 mg weekly, titrated up). Step 3: If glycemic target not achieved and weight loss is a priority, consider switching to tirzepatide or adding an SGLT2 inhibitor. Step 4: If HbA1c still >8% after dual therapy, add basal insulin. This protocol emphasizes early use of GLP-1 RA for weight and CV protection, with stepwise intensification only as needed.

For a patient with established ASCVD and/or CKD (eGFR 40 mL/min/1.73m², UACR 300 mg/g), an SGLT2 inhibitor should be initiated alongside metformin and a GLP-1 RA (e.g., dulaglutide or semaglutide) regardless of HbA1c, per guideline recommendations <sup>1</sup>.

Conclusion: An Integral Component of Modern Diabetes Management

Incretin-based therapies have progressed from a niche adjunct to a central pillar of type 2 diabetes treatment. By restoring the diminished incretin effect, GLP-1 receptor agonists and DPP-4 inhibitors provide effective glycemic control with low hypoglycemia risk, and certain agents offer substantial cardiovascular and weight-related benefits. The choice between classes depends on individual patient characteristics, preferences, cost, and tolerance. With ongoing development of novel agents and combinations, the role of incretin-based therapies is set to expand further, offering new possibilities for comprehensive metabolic disease management. Clinicians must remain informed about emerging evidence and guideline updates to optimally integrate these therapies into patient-centered protocols.

References

  1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S158–S178. <a href="https://doi.org/10.2337/dc24-S009" target="_blank" rel="noopener">doi:10.2337/dc24-S009</a>
  2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786. <a href="https://doi.org/10.2337/dci22-0034" target="_blank" rel="noopener">doi:10.2337/dci22-0034</a>
  3. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors and GLP-1 receptor agonists: complementary roles in cardiorenal protection. JAMA. 2022;328(1):48–49. <a href="https://doi.org/10.1001/jama.2022.11032" target="_blank" rel="noopener">doi:10.1001/jama.2022.11032</a>
  4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. <a href="https://doi.org/10.1056/NEJMoa1603827" target="_blank" rel="noopener">doi:10.1056/NEJMoa1603827</a>
  5. Pratley RE, Sattar N, Jensen ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes and overweight or obesity: the SELECT trial. N Engl J Med. 2023;389(23):2161–2173. <a href="https://doi.org/10.1056/NEJMoa2308563" target="_blank" rel="noopener">doi:10.1056/NEJMoa2308563</a>